GILD241227C95000
- 0.21
- +0.02+10.53%
Gilead Sciences Newsroom
Gilead Sciences Invests $20.1 Million in Assembly Biosciences
Gilead Sciences (GILD) Made Big Announcements in Q3
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
Gilead Sciences to Present at Upcoming Investor Conference
19% Of This Gilead Sciences Insider's Holdings Were Sold
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences Acquires $1.83 Million in Xilio Therapeutics Stock
Gilead Sciences Acquires 7.85M Xilio Therapeutics Shares At $1.04 Each, Raising Ownership To Over 10%, Along With 6.1M Pre-Funded Warrants Capped At 19.99% Ownership
(GILD) - Analyzing Gilead Sciences's Short Interest
Gilead Raises Assembly Bio Stake to ~30%
Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding
Press Release: Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding From Gilead to Advance Clinical Development Programs
Express News | Merck's two late-stage studies on AIDS therapies have achieved their primary goals.
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
Gilead Gets FDA Breakthrough Therapy Status for Trodelvy
4 Big Drug Stocks That May Continue to Outperform in 2025
Express News | U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (Sacituzumab Govitecan-Hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Gilead Sciences And Terray Therapeutics Have Entered Into A Strategic Collaboration To Discover And Develop Novel, Small Molecule Therapies Across Multiple Targets